References
- Kimmel B, Inzucchi S. Oral agents for type 2 diabetes: an update. Clin Diabetes. 2005;23:64–76.10.2337/diaclin.23.2.64
- Woerle HJ, Pimenta WP, Meyer C, et al. Diagnostic and therapeutic implications of relationships between fasting, 2-h postchallenge plasma glucose and hemoglobin A1c values. Arch Intern Med. 2004;164:1627–1632.10.1001/archinte.164.15.1627
- Casirola DM, Ferraris RP. α-Glucosidase inhibitors prevent diet-induced increases in intestinal sugar transport in diabetic mice. Metabolism. 2006;55:832–841.10.1016/j.metabol.2006.02.011
- Zhang L, Hogan S, Li JR, et al. Grape skin extract inhibits mammalian intestinal α-glucosidase activity and suppresses postprandial glycemic response in streptozocin-treated mice. Food Chem. 2011;126:466–471.10.1016/j.foodchem.2010.11.016
- Madar Z. The effect of acarbose and miglitol (BAY-M-1099) on postprandial glucose levels following ingestion of various sources of starch by non-diabetic and streptozotocin-induced diabetic rats. J Nutr. 1989;119:2023–2029.
- Murai A, Iwamura K, Takada M, et al. Control of postprandial hyperglycaemia by galactosyl maltobionolactone and its novel anti-amylase effect in mice. Life Sci. 2002;71:1405–1415.10.1016/S0024-3205(02)01844-1
- Fujisawa T, Ikegami H, Inoue K, et al. Effect of two α-glucosidase inhibitors, voglibose and acarbose, on postprandial hyperglycemia correlates with subjective abdominal symptoms. Metabolism. 2005;54:387–390.10.1016/j.metabol.2004.10.004
- Ceriello A, Esposito K, Piconi L, et al. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes. 2008;56:2806–2821.
- Tabassum N, Chatturvedi S, Agrawal SS. Effect of Tamarix gallica leaves on experimental liver cell injury. JK-Pract. 2016;13:43–44.
- Ksouri R, Falleh H, Megdiche W, et al. Antioxidant and antimicrobial activities of the edible medicinal halophyte Tamarix gallica L. and related polyphenolic constituents. Food Chem Toxicol. 2009;47:2083–2091.10.1016/j.fct.2009.05.040
- Mayuresh R, Andrzej P, Patrycja LK, et al. Herbal medicine for treatment and prevention of liver diseases. J Pre-Clin Clin Res. 2014;8:55–60.
- Saewan N, Koysomboom S, Chantrapromma K. Anti-tyrosinase and anti-cancer activities of flavonoids from Blumea balsamifera DC. J Med Plants Res. 2011;18:1018–1025.
- Paya M, Manez S, Villar A. Flavonoid constituents of Rhamnus lycioides L. Z. Naturforsch. 1986;41c: 976–978.
- Nawwar MAM, Souleman AMA, Buddrus J, et al. Flavonoids of the flowers of Tamarix nilotica. Phytochemistry. 1984;23:2347–2349.10.1016/S0031-9422(00)80549-X
- Cheng Y, Prusoff WH. Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 1973;22:3099–3108.
- Rodier M, Richard JL, Monnier L, et al. Effect of long term acarbose (Bay g 5421) therapy on metabolic control of non insulin dependent (type II) diabetes mellitus. Diabetes Metab. 1988;14:12–14.
- Santeusanio F, Ventura MM, Contadinbi S. Efficacy and safety of two different dosages of acarbose in non-insulin dependent diabetic patients treated by diet alone. Diabetes Nutr Metab. 1993;6:147–154.
- Hanefeld M, Fischer S, Schulze J, et al. Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone. Diabetes Care. 1991;14:732–737.10.2337/diacare.14.8.732